Drugs / WSD0922-FU
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04197934 | Dec 2019 → Oct 2022 overdue | IDH-wildtype anaplastic astrocytoma, IDH-wildtype glioblastoma, non-small cell lung carcinoma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07206498 | Oct 2025 → Oct 2028 expected | non-small cell lung carcinoma | Wayshine Biopharm, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06631989 | Sep 2024 → Jun 2027 expected | lung cancer | Wayshine Biopharm, Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07708961 | Aug 2026 → Aug 2036 | IDH-wildtype glioblastoma | Mayo Clinic | Suspended | No outcome recorded |
| Phase 2 | NCT06868485 | Aug 2025 → Sep 2027 expected | non-small cell lung carcinoma | Wayshine Biopharm, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WSD0922-FU | “WSD0922-FU” NCT04197934 ↗ |
| Action | Inhibit | “blocks the EGFR protein” NCT04197934 ↗ |
| Route | Oral | “Given PO” NCT04197934 ↗ |
| Target | EGFR | “blocks the EGFR protein” NCT04197934 ↗ |